argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Wells Fargo & Company from $639.00 to $723.00. They now have an "overweight" rating on the stock.
Should You Increase Your Holdings in argenx SE (ARGX)? [Yahoo! Finance]
argenx SE (NASDAQ: ARGX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $655.00 price target on the stock.
Why Is Argenx SE (ARGX) Among the Best High Growth Healthcare Stocks to Invest In Now? [Yahoo! Finance]